© 2012 CareFusion Corporation or one of its subsidiaries. All rights reserved. 2 Safe Harbor and Additional Information “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion’s Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently operating under an amended consent decree with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. This presentation reflects management’s views as of May 3, 2012. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement. Non-GAAP Financial Measures: The financial information included in this presentation includes Non-GAAP financial measures. Reconciliations can be found on slides 19 and 20 of this presentation. In addition, definitions and reconciling information can be found on CareFusion’s website at www.carefusion.com under the Investors tab. New Reporting Segments: Commencing with the quarter ended September 30, 2011, CareFusion began reporting financial results based on its two new operating and reportable segments, Medical Systems and Procedural Solutions. The financial information contained in this presentation reflects these new segments, which replaced the Critical Care Technologies and Medical Technologies and Services segments under which the company had previously reported. The Medical Systems segment includes the company’s Dispensing Technologies, Infusion Systems and Respiratory Technologies business lines. The Procedural Solutions segment includes the company’s Infection Prevention, Medical Specialties and Specialty Disposables business lines. The company has separately provided summary historical financial data for the new reportable segments in a report on Form 8-K filed with the Securities and Exchange Commission on November 2, 2011. Nicolet Divestiture: On April 23, 2012, the company announced it had entered into an agreement to sell its Nicolet neurodiagnostic and monitoring business. Results from the Nicolet business, which had been included in the Other sub-segment of the Procedural Solutions segment have been classified as discontinued operations as of March 31, 2012. Reported results for continuing operations and comparisons to prior periods exclude the historical results of the Nicolet business. Previously reported results have been adjusted to reflect the impact of the re-segmentation of CareFusion’s businesses and the divestiture of the International Surgical Products (ISP) business. The ISP business was divested in April 2011, and has been classified as discontinued operations. Comparisons to prior periods exclude the historical results of the ISP business. | 
